- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Mylan launches generic version of Prandin
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Lipitor may be the first statin to switch to OTC
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
INDIANAPOLIS — Eli Lilly and Company on Tuesday reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.
"Lilly delivered solid financial results in the fourth quarter of 2012, as we successfully offset a large part of the revenue decline from the Zyprexa patent expiration with growth in other products such as Cymbalta, Forteo, Alimta, Effient and our animal health portfolio," stated John Lechleiter, Lilly's chairman, president and CEO. "At the same time, we continued to control costs while investing in R&D in order to replenish and advance our pipeline. Today, Lilly has 13 potential new medicines in Phase III testing. We are well-positioned to deliver on our innovation-based strategy and create long-term value for all of our stakeholders."
Find us on Facebook for even more insight, analysis and the latest in drug store news.